Qualigen Therapeutics Board Changes Announced
Ticker: AIXC · Form: 8-K · Filed: Sep 26, 2024 · CIK: 1460702
Sentiment: neutral
Topics: board-changes, executive-compensation, director-resignation, director-appointment
Related Tickers: QLGN
TL;DR
Qualigen board shake-up: Hastings in, Smith out. New exec pay details.
AI Summary
Qualigen Therapeutics, Inc. announced on September 23, 2024, a change in its board of directors. Specifically, Dr. Paul J. Hastings has been appointed as a new director, and Mr. Steven R. Smith has resigned from the board. The company also disclosed compensatory arrangements for certain officers.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board changes and executive compensation disclosures can introduce uncertainty about future strategic direction and financial commitments.
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- Dr. Paul J. Hastings (person) — Newly appointed director
- Mr. Steven R. Smith (person) — Resigned director
- September 23, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed to the Qualigen Therapeutics board of directors?
Dr. Paul J. Hastings has been appointed as a new director.
Who has resigned from the Qualigen Therapeutics board of directors?
Mr. Steven R. Smith has resigned from the board.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is September 23, 2024.
What other information is disclosed regarding officers in this filing?
The filing also discloses compensatory arrangements of certain officers.
What is the principal executive office address for Qualigen Therapeutics, Inc.?
The address of the principal executive offices is 5857 Owens Avenue, Suite 300, Carlsbad, California 92008.
Filing Stats: 715 words · 3 min read · ~2 pages · Grade level 11.7 · Accepted 2024-09-26 17:10:13
Key Financial Figures
- $4,500 — ing fee for Mr. Richardson shall be USD $4,500 per week. Mr. Richardson has extensive
- $20m — dson took from a fledgling operation to $20mm in revenue. Item 8.01 Other Events.
Filing Documents
- form8-k.htm (8-K) — 36KB
- 0001493152-24-038351.txt ( ) — 208KB
- qlgn-20240923.xsd (EX-101.SCH) — 3KB
- qlgn-20240923_lab.xml (EX-101.LAB) — 33KB
- qlgn-20240923_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: September 26, 2024 By: /s/ Campbell Becher Campbell Becher, President